JP2023547607A5 - - Google Patents

Info

Publication number
JP2023547607A5
JP2023547607A5 JP2023523309A JP2023523309A JP2023547607A5 JP 2023547607 A5 JP2023547607 A5 JP 2023547607A5 JP 2023523309 A JP2023523309 A JP 2023523309A JP 2023523309 A JP2023523309 A JP 2023523309A JP 2023547607 A5 JP2023547607 A5 JP 2023547607A5
Authority
JP
Japan
Prior art keywords
sustained
biodegradable intraocular
release biodegradable
intraocular implant
implant according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547607A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056648 external-priority patent/WO2022093818A1/en
Publication of JP2023547607A publication Critical patent/JP2023547607A/ja
Publication of JP2023547607A5 publication Critical patent/JP2023547607A5/ja
Pending legal-status Critical Current

Links

JP2023523309A 2020-10-27 2021-10-26 活性薬剤を含む眼内インプラント Pending JP2023547607A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063106270P 2020-10-27 2020-10-27
US63/106,270 2020-10-27
US202163165423P 2021-03-24 2021-03-24
US63/165,423 2021-03-24
US202163209725P 2021-06-11 2021-06-11
US63/209,725 2021-06-11
PCT/US2021/056648 WO2022093818A1 (en) 2020-10-27 2021-10-26 Ocular implant containing an active agent

Publications (2)

Publication Number Publication Date
JP2023547607A JP2023547607A (ja) 2023-11-13
JP2023547607A5 true JP2023547607A5 (cg-RX-API-DMAC7.html) 2025-06-09

Family

ID=81383236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523309A Pending JP2023547607A (ja) 2020-10-27 2021-10-26 活性薬剤を含む眼内インプラント

Country Status (10)

Country Link
US (2) US20230390189A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236943A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023547607A (cg-RX-API-DMAC7.html)
KR (1) KR20230097020A (cg-RX-API-DMAC7.html)
CN (1) CN116419755A (cg-RX-API-DMAC7.html)
AU (1) AU2021367970A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192909A1 (cg-RX-API-DMAC7.html)
IL (1) IL301640A (cg-RX-API-DMAC7.html)
MX (1) MX2023004614A (cg-RX-API-DMAC7.html)
WO (1) WO2022093818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
PT3884929T (pt) * 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
US20260108561A1 (en) * 2022-10-04 2026-04-23 National University Of Singapore Composition for cell transplantation therapy and the use thereof
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
PE20260040A1 (es) * 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa
CN120459009A (zh) * 2024-04-29 2025-08-12 浙江瑞瞳生物科技有限公司 可降解泪小管插入剂及制备方法
WO2025248489A1 (en) * 2024-05-29 2025-12-04 Sight Sciences, Inc. Bio-erodible ocular implants for treatment of conditions of the eye
WO2025255203A1 (en) * 2024-06-06 2025-12-11 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
CN119185164A (zh) * 2024-09-09 2024-12-27 沈阳药科大学 一种高载药量的抗vegf眼内缓释植入剂及其制备方法
CN120571053A (zh) * 2025-06-19 2025-09-02 青岛大学附属医院 一种用于密封视网膜裂孔的可荧光示踪的水凝胶材料及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003124B2 (en) * 2005-04-08 2011-08-23 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US10226417B2 (en) * 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US10465188B2 (en) * 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
EP4279064A3 (en) * 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
PT3884929T (pt) * 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
CN114533648B (zh) * 2020-11-26 2026-04-07 成都康弘药业集团股份有限公司 一种阿西替尼眼内植入剂

Similar Documents

Publication Publication Date Title
JP2023547607A5 (cg-RX-API-DMAC7.html)
Bernkop-Schnürch et al. Thiolated chitosans
US12338330B2 (en) Alginate hydrogel compositions
JP5539725B2 (ja) 分岐末端反応物及びそれから製造されるポリマーヒドロゲル組織接着剤
JP2023512715A5 (cg-RX-API-DMAC7.html)
Sreenivas et al. Thiolated chitosans: novel polymers for mucoadhesive drug delivery–a review
ES2262182T3 (es) Metodos y composiciones para reducir o eliminar la formacion de adherencias postoperatorias.
US20070233240A1 (en) Intraocular lens implant
US8628789B2 (en) Strong reversible hydrogels
JP2006519049A (ja) 医療機器のためのポリマーネットワークシステム及び使用方法
Hanif et al. Thiomers: a blessing to evaluating era of pharmaceuticals
Chivukula et al. Synthesis and characterization of novel aromatic azo bond-containing pH-sensitive and hydrolytically cleavable IPN hydrogels
JP5047793B2 (ja) 安定化されたプロスタグランジン組成物
PT2093245E (pt) Dispositivo biocompatível de polímeros
CN102639163A (zh) 组织扩张器
JP2011074075A (ja) 多機構外科用組成物
EP1203784A1 (en) Polymer, in vivo degradable material, and use
CZ386797A3 (cs) Přípravek k prevenci a hojení zánětlivých onemocnění
ES3060983T3 (en) Injectable cushioning hydrogels
JP2022021475A (ja) 腱又は靭帯の治療用ゲル材料
CN112812263B (zh) 一种自愈合水凝胶的制备方法与应用
JP2004506688A (ja) 損傷、および他の適応症の治療
JP2008502388A (ja) 隔膜
CN105358185B (zh) 用于再生医学和组织工程的可生物降解的网络聚合物
JP2022545893A5 (cg-RX-API-DMAC7.html)